2025
SJR Q1
JCR Q1 · 4,2
336 eşleşen makale
SCIE
Dergi ayrıntısı
Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Yayıncı
- Elsevier Inc.
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0278584618784216
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 1,502
- Quartile Q1
- H-Index 165
- Atıf/yayın 4,93
- Doküman (3y) 551
- Atıf (3y) 2.833
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 4,2
- 5Y JIF 5
- JCI 1,11
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,502 | 4,2 | 5 | 1,11 | Q1 | 165 |
| 2024 | Q1 | Q1 | 1,768 | 3,9 | 4,8 | 1,41 | Q1 | 157 |
| 2023 | Q1 | Q1 | 1,652 | 5,3 | 4,9 | 1,43 | Q1 | 157 |
| 2022 | Q1 | Q1 | 1,543 | 5,6 | 5,3 | 1,48 | Q1 | 157 |
| 2021 | Q1 | Q2 | 1,37 | 5,2 | 5,5 | 1,19 | Q1 | 157 |
| 2020 | Q1 | Q1 | 1,716 | 5,1 | 4,9 | 1,26 | Q1 | 157 |
| 2019 | Q1 | Q1 | 1,714 | 4,4 | 4,2 | 1,48 | Q1 | 157 |
| 2018 | — | Q1 | — | 4,3 | 4,2 | 1,4 | Q1 | — |
| 2017 | Q1 | Q1 | 1,714 | 4,2 | 4 | 1,56 | Q1 | 157 |
| 2016 | Q1 | Q1 | 1,929 | 4,2 | 4,1 | — | — | 157 |
| 2015 | Q1 | Q1 | 1,819 | 4,4 | 4,1 | — | — | 157 |
| 2014 | Q1 | Q1 | 1,789 | 3,7 | 3,8 | — | — | 157 |
| 2013 | Q1 | Q1 | 1,752 | 4 | 3,8 | — | — | 157 |
| 2012 | Q1 | Q1 | 1,688 | 3,6 | 3,5 | — | — | 157 |
| 2011 | Q1 | Q1 | 1,337 | 3,2 | 3,1 | — | — | 157 |
| 2010 | Q1 | Q2 | 1,317 | 2,9 | 3 | — | — | 157 |
| 2009 | — | Q2 | — | 2,8 | 2,9 | — | — | — |
| 2008 | — | Q2 | — | 2,6 | 3,2 | — | — | — |
| 2007 | — | Q2 | — | 2,8 | 2,8 | — | — | — |
| 2006 | — | Q2 | — | 2,6 | — | — | — | — |
| 2005 | — | Q1 | — | 2,8 | — | — | — | — |
| 2004 | — | Q2 | — | 2,1 | — | — | — | — |
| 2003 | — | Q2 | — | 1,8 | — | — | — | — |
| 2002 | — | Q2 | — | 1,4 | — | — | — | — |
| 2001 | — | Q3 | — | 1,1 | — | — | — | — |
| 2000 | — | Q3 | — | 1,1 | — | — | — | — |
| 1999 | — | Q2 | — | 1,4 | — | — | — | — |
| 1998 | — | Q2 | — | 1,1 | — | — | — | — |
| 1997 | — | Q3 | — | 0,8 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 61/296 |
| 2025 | NEUROSCIENCES | SCIE | Q2 | Q1 | 103/330 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 102/356 |
| 2025 | PSYCHIATRY | SCIE | Q1 | Q1 | 62/293 |
| 2024 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 59/286 |
| 2024 | NEUROSCIENCES | SCIE | Q2 | Q1 | 86/314 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 88/352 |
| 2024 | PSYCHIATRY | SCIE | Q1 | Q1 | 55/288 |
| 2023 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 29/280 |
| 2023 | NEUROSCIENCES | SCIE | Q1 | Q1 | 44/310 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 35/354 |
| 2023 | PSYCHIATRY | SCIE | Q1 | Q1 | 28/279 |
| 2022 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 37/212 |
| 2022 | NEUROSCIENCES | SCIE | Q1 | Q1 | 53/272 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 44/278 |
| 2022 | PSYCHIATRY | SCIE | Q2 | Q1 | 39/155 |
| 2021 | CLINICAL NEUROLOGY | SCIE | Q2 | Q1 | 55/212 |
| 2021 | NEUROSCIENCES | SCIE | Q2 | Q1 | 85/275 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q1 | 70/279 |
| 2021 | PSYCHIATRY | SCIE | Q2 | Q1 | 55/155 |
| 2020 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 48/208 |
| 2020 | NEUROSCIENCES | SCIE | Q2 | Q1 | 81/273 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 63/276 |
| 2020 | PSYCHIATRY | SCIE | Q1 | Q1 | 35/156 |
| 2019 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 41/204 |
| 2019 | NEUROSCIENCES | SCIE | Q2 | Q1 | 74/272 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 45/271 |
| 2019 | PSYCHIATRY | SCIE | Q1 | Q1 | 31/155 |
| 2018 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 38/199 |
| 2018 | NEUROSCIENCES | SCIE | Q2 | Q1 | 68/267 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 41/267 |
| 2018 | PSYCHIATRY | SCIE | Q1 | Q1 | 28/146 |
| 2017 | CLINICAL NEUROLOGY | SCIE | Q1 | Q1 | 39/197 |
| 2017 | NEUROSCIENCES | SCIE | Q2 | Q1 | 66/261 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 38/261 |
| 2017 | PSYCHIATRY | SCIE | Q1 | Q1 | 28/142 |
| 2016 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 36/194 |
| 2016 | NEUROSCIENCES | SCIE | Q1 | — | 63/259 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 41/257 |
| 2016 | PSYCHIATRY | SCIE | Q1 | — | 28/142 |
| 2015 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 34/193 |
| 2015 | NEUROSCIENCES | SCIE | Q1 | — | 59/256 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 37/255 |
| 2015 | PSYCHIATRY | SCIE | Q1 | — | 27/142 |
| 2014 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 41/192 |
| 2014 | NEUROSCIENCES | SCIE | Q2 | — | 78/252 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 55/255 |
| 2014 | PSYCHIATRY | SCIE | Q2 | — | 36/140 |
| 2013 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 33/194 |
| 2013 | NEUROSCIENCES | SCIE | Q2 | — | 74/252 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 36/256 |
| 2013 | PSYCHIATRY | SCIE | Q1 | — | 29/136 |
| 2012 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 39/193 |
| 2012 | NEUROSCIENCES | SCIE | Q2 | — | 86/252 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 55/261 |
| 2012 | PSYCHIATRY | SCIE | Q1 | — | 31/135 |
| 2011 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 51/192 |
| 2011 | NEUROSCIENCES | SCIE | Q2 | — | 98/244 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 64/261 |
| 2011 | PSYCHIATRY | SCIE | Q2 | — | 36/130 |
| 2010 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 61/185 |
| 2010 | NEUROSCIENCES | SCIE | Q2 | — | 115/239 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 83/252 |
| 2010 | PSYCHIATRY | SCIE | Q2 | — | 42/128 |
| 2009 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 55/167 |
| 2009 | NEUROSCIENCES | SCIE | Q2 | — | 115/231 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 85/237 |
| 2009 | PSYCHIATRY | SCIE | Q2 | — | 43/117 |
| 2008 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 55/156 |
| 2008 | NEUROSCIENCES | SCIE | Q2 | — | 109/221 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 85/219 |
| 2008 | PSYCHIATRY | SCIE | Q2 | — | 43/101 |
| 2007 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 40/146 |
| 2007 | NEUROSCIENCES | SCIE | Q2 | — | 87/211 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 66/205 |
| 2007 | PSYCHIATRY | SCIE | Q2 | — | 36/94 |
| 2006 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 45/147 |
| 2006 | NEUROSCIENCES | SCIE | Q2 | — | 97/200 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 68/199 |
| 2006 | PSYCHIATRY | SCIE | Q2 | — | 35/94 |
| 2005 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 32/148 |
| 2005 | NEUROSCIENCES | SCIE | Q2 | — | 78/200 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 53/193 |
| 2005 | PSYCHIATRY | SCIE | Q2 | — | 32/94 |
| 2004 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 52/140 |
| 2004 | NEUROSCIENCES | SCIE | Q3 | — | 108/198 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 70/187 |
| 2004 | PSYCHIATRY | SCIE | Q2 | — | 39/90 |
| 2003 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 57/135 |
| 2003 | NEUROSCIENCES | SCIE | Q3 | — | 116/198 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 89/185 |
| 2003 | PSYCHIATRY | SCIE | Q3 | — | 45/87 |
| 2002 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 65/138 |
| 2002 | NEUROSCIENCES | SCIE | Q3 | — | 128/197 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 100/188 |
| 2002 | PSYCHIATRY | SCIE | Q3 | — | 57/88 |
| 2001 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 75/136 |
| 2001 | NEUROSCIENCES | SCIE | Q3 | — | 140/198 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 118/186 |
| 2001 | PSYCHIATRY | SCIE | Q3 | — | 55/81 |
| 2000 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 70/137 |
| 2000 | NEUROSCIENCES | SCIE | Q3 | — | 134/203 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 109/181 |
| 2000 | PSYCHIATRY | SCIE | Q3 | — | 53/82 |
| 1999 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 58/132 |
| 1999 | NEUROSCIENCES | SCIE | Q3 | — | 119/201 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 73/175 |
| 1999 | PSYCHIATRY | SCIE | Q2 | — | 39/80 |
| 1998 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 59/125 |
| 1998 | NEUROSCIENCES | SCIE | Q3 | — | 126/202 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 91/178 |
| 1998 | PSYCHIATRY | SCIE | Q3 | — | 42/77 |
| 1997 | CLINICAL NEUROLOGY | SCIE | Q3 | — | 66/107 |
| 1997 | NEUROSCIENCES | SCIE | Q4 | — | 126/150 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 103/157 |
| 1997 | PSYCHIATRY | SCIE | Q3 | — | 45/67 |